Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Rhea-AI Summary
Greenwich LifeSciences (Nasdaq: GLSI) received a notice from Nasdaq on April 16, 2026, for noncompliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The notice does not affect the current listing or trading of GLSI common stock. The company says it will file the Form 10-K as soon as possible, coordinating with two auditors who are each responsible for their respective periods in 2024 and 2025.
Positive
- Common stock continues trading on Nasdaq Capital Market
- Company plans to file the Form 10-K as soon as possible
- Two auditors assigned, each responsible for specific periods
Negative
- Not currently in compliance with Nasdaq Rule 5250(c)(1)
- Annual Report on Form 10-K for FY 2025 remains unfiled as of April 16, 2026
News Market Reaction – GLSI
In the Apr 23 session, GLSI declined 5.09%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Clinical data update | Positive | -11.6% | Phase III FLAMINGO-01 open-label immune response data presented at AACR 2026. |
| Apr 14 | Financing update | Positive | -5.3% | ATM-driven cash raise exceeding Q1 2026 cash burn for trial funding. |
| Apr 07 | Patent expansion | Positive | +2.2% | New patent claims potentially doubling GP2 market to 88,000 patients/year. |
| Mar 19 | Trial site expansion | Positive | -3.1% | Addition of City of Hope network sites to FLAMINGO-01 Phase III trial. |
| Mar 18 | Conference abstracts | Positive | -11.1% | AACR 2026 abstracts on FLAMINGO-01 immune response data and study design. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent GLSI news has often seen negative price reactions even to seemingly positive clinical and corporate updates, with only one of the last five events showing an aligned positive move.
This announcement follows a series of GLSI updates centered on its Phase III FLAMINGO‑01 trial and financing. On Mar 18 and Mar 19, the company highlighted AACR presentations and new City of Hope trial sites, yet shares fell after both. An April 7 patent update implying a 100% market expansion saw a modest gain, while the April 14 financing update and April 20 FLAMINGO‑01 immune‑response data both drew share price declines. Against that backdrop, a late Form 10‑K notice introduces a compliance-focused, non‑clinical catalyst.
Key Terms
phase iii medical
immunotherapy medical
fast track regulatory
form 10-k regulatory
nasdaq listing rule 5250(c)(1) regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."
The Company plans to file its Form 10-K for the fiscal year ended December 31, 2025 as soon as possible, working with both of its auditors where each auditor is responsible for their own periods ending in 2024 and 2025.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
